ATAZANAVIR TEVA 150 mg, hard capsule 60 capsules
Active ingredients: Atazanavir, Atazanavir sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ATAZANAVIR TEVA 150 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC de 60 gélule(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 26 Apr 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62766073CIP73004256CIP133400930042564Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ATAZANAVIRgélule | 150 mg · une gélule | FT |
| SULFATE D'ATAZANAVIRgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.